Last reviewed · How we verify
Metoprolol (MET)
Metoprolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate, blood pressure, and cardiac workload.
Metoprolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Angina pectoris, Acute myocardial infarction.
At a glance
| Generic name | Metoprolol (MET) |
|---|---|
| Also known as | metoprolol 25mg |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Drug class | Beta-1 selective adrenergic receptor antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Metoprolol selectively blocks beta-1 adrenergic receptors on the heart and blood vessels, reducing the effects of norepinephrine and epinephrine. This decreases heart rate, contractility, and blood pressure, thereby reducing myocardial oxygen demand. It is used to manage hypertension, angina, heart failure, and arrhythmias.
Approved indications
- Hypertension
- Angina pectoris
- Acute myocardial infarction
- Heart failure
- Atrial fibrillation
- Essential tremor
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Dyspnea
- Depression
- Sexual dysfunction
Key clinical trials
- Early Beta Blocker Administration in STEMI Patients With SCAI B Status (NA)
- Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension (PHASE3)
- Anti Inflammatory Treatment of Hypertension (PHASE2, PHASE3)
- Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metoprolol (MET) CI brief — competitive landscape report
- Metoprolol (MET) updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI